


# Breast Cancer

## MARKET & PIPELINE

### Epidemiology data




### Key Market Data

**28**  
marketed  
biologics  
products\*



**13** Monoclonal Antibodies



**3** Monoclonal Antibodies Conjugated

### Active biologics pipeline


Triple-negative Breast Cancer - **30%**

Metastatic - **15%**

HER2+ - **12%**

### Drugs by Indication

### Drugs by Molecule Type



\*Innovative Therapies (exclude Biosimilars)